ACRV Acrivon Therapeutics Inc
Price (delayed)
$1.81
Market cap
$56.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.38
Enterprise value
$20.38M
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our
Highlights
Acrivon Therapeutics's debt has decreased by 22% YoY and by 9% QoQ
The EPS has grown by 13% YoY and by 12% from the previous quarter
ACRV's equity is up by 46% YoY but it is down by 10% QoQ
ACRV's quick ratio is down by 18% from the previous quarter but it is up by 9% YoY
ACRV's net income is down by 33% year-on-year and by 4.6% since the previous quarter
Key stats
What are the main financial stats of ACRV
Market
Valuations
Earnings
Shares outstanding
31.35M
Market cap
$56.75M
Enterprise value
$20.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.32
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$89.2M
Net income
-$80.56M
EBIT
-$80.56M
EBITDA
-$78.62M
Free cash flow
-$68.44M
Per share
Balance sheet
Liquidity
EPS
-$2.38
EPS diluted
-$2.38
Free cash flow per share
-$2.03
Book value per share
$5.68
Revenue per share
$0
TBVPS
$5.82
Total assets
$196.59M
Total liabilities
$19.8M
Debt
$3.65M
Equity
$176.79M
Working capital
$164.42M
Debt to equity
0.02
Current ratio
10.55
Quick ratio
10.44
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.3%
Return on equity
-46.2%
Return on invested capital
-56.4%
Return on capital employed
-44.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRV stock price
How has the Acrivon Therapeutics stock price performed over time
Intraday
-2.16%
1 week
18.3%
1 month
-67.09%
1 year
-82.5%
YTD
-69.93%
QTD
-10.84%
Financial performance
How have Acrivon Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$89.2M
Net income
-$80.56M
Gross margin
N/A
Net margin
N/A
ACRV's net income is down by 33% year-on-year and by 4.6% since the previous quarter
The operating income has declined by 33% year-on-year and by 4.6% since the previous quarter
Growth
What is Acrivon Therapeutics's growth rate over time
Valuation
What is Acrivon Therapeutics stock price valuation
P/E
N/A
P/B
0.32
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 13% YoY and by 12% from the previous quarter
The P/B is 71% below the last 4 quarters average of 1.1
ACRV's equity is up by 46% YoY but it is down by 10% QoQ
Efficiency
How efficient is Acrivon Therapeutics business performance
The ROIC has contracted by 10% YoY but it has grown by 4.4% from the previous quarter
Acrivon Therapeutics's return on equity has decreased by 9% YoY but it has increased by 3.8% QoQ
The ROA has contracted by 8% YoY but it has grown by 3.2% from the previous quarter
Dividends
What is ACRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRV.
Financial health
How did Acrivon Therapeutics financials performed over time
The total assets is up by 42% year-on-year but it is down by 8% since the previous quarter
ACRV's quick ratio is down by 18% from the previous quarter but it is up by 9% YoY
Acrivon Therapeutics's debt is 98% lower than its equity
The debt to equity has dropped by 50% year-on-year
ACRV's equity is up by 46% YoY but it is down by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.